Biocon share price jumped over 4% on Tuesday after the company announced that its subsidiary has secured market entry date for Yesafili, an interchangeable biosimilar to Eylea, in the US. Biocon ...

BENGALURU: Biocon Foundation, the Corporate Social Responsibility (CSR) arm of Biocon Group marked two decades of commitment to social impact and community development. To commemorate this ...

Shares of Biocon surged over 4 percent on January 14 after brokerage firm HSBC upgraded the stock to a 'buy' call amid expectations of a turnaround for the drugmaker. HSBC also lifted its price ...

International brokerage Jefferies has upgraded its rating on drugmaker Biocon to 'hold' citing positive newsflow around the regulatory approval of its Bengaluru manufacturing unit. Building on the ...

To stay informed about Biocon’s Q1 results, you can access the live webcast of the announcement on the company's official website. Biocon Q1 FY25 Results: Biocon, a leading biopharmaceutical ...

Biocon shares were trading higher by 2.41 per cent, or Rs 6.35, at Rs 269.45 each at 11:09 am on Thursday. Biocon said that it had signed "an exclusive licensing and supply agreement with Biomm S.A., ...

As part of the agreement, Biocon Biologics, a fully integrated global biosimilars company, will expand patient access to its portfolio of metabolics, oncology and critical care products in the country ...

In Biocon’s continuing effort to divest and Eris Lifesciences’ attempt to grow, the companies have expanded a previous agreement, with Bangalore-based generics giant Biocon selling Indian ...

BENGALURU, March 14 (Reuters) - Biopharmaceutical company Biocon's (BION.NS), opens new tab unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences (ERIS.NS ...

Bengaluru: Biocon Limited today announced its inclusion in S&P’s Sustainability Yearbook 2024 for the second consecutive year, based on the S&P Global Corporate Sustainability Assessment (CSA ...

Bengaluru: Biocon’s recorded a revenue of Rs 4,519 crore for the December quarter, up 50% compared to the same period last year. While the generics business of the bio-pharmaceutical company ...